Table 4.

Comparison of antibiotic susceptibilities of the Streptococcus pneumoniae nasopharyngeal isolates during PCV7 versus PCV13 eras.

		PCV7			PCV13
Antibiotics	Antibiotics sensitivity range in μg/ml	Percentage of Spn isolates (n=210)			Prcentage Spn isolates (n=438)			p-value of change in Resistance
	(S; I; R)	S	I	R	S	I	R
Benzylpenicillin	<=.06;.12-1;>=2	55.7	31.4	12.9	68.5	27.2	4.3	<0.001
Amoxacillin /Calvulanic Acid	<=2;I4;R>=8	100.0	0.0	0.0	98.4	1.1	0.5	ns
Cefotaxime	<=.5;1;>=2	84.3	10.0	5.7	93.4	0.5	6.1	ns/0.01*
Ceftriaxone	<=1;2;>=4	84.7	8.6	6.7	96.8	2.3	0.9	<0.0001
Ertapenem	<=1;2;>=4	98.6	1.4	0.0	98.1	0.9	0.0	ns
Meropenem	<=.25;.5;>=1	84.8	12.9	2.4	87.8	10.1	2.1	ns
Levofloxacin	<=2;4;>=8	100.0	0.0	0.0	100.0	0.0	0.0	ns
Moxifloxacin	<=1;2;>=4	100.0	0.0	0.0	100.0	0.0	0.0	ns
Ofloxacin	<=2;4;>=8	100.0	0.0	0.0	99.6	0.2	0.2	ns
Erythromycin	<=.25;.5;>=1	70.0	0.0	30.0	84.2	0.0	15.8	<0.0001
Telithromycin	<=1;2;>=4	100.0	0.0	0.0	100.0	0.0	0.0	ns
Linezolid	<=2	100.0	-	0.0	100.0	-	0.0	ns
Vancomycin	<=1	100.0	-	0.0	98.6	-	1.4	ns
Tetracycline	<=2;4;>=8	80.5	0.5	19.0	94.1	0.9	5.0	<0.0001
Chloramphenicol	<=4S;>=8R	98.6	-	1.4	100.0	-	0.0	0.01
Trimethoprim/Sulfamethoxazole	<=9.5;19-38;>=76	73.3	4.3	22.4	87.2	6.1	6.6	<0.0001

S: sensitive; I: intermediate; R: resistant; ns: not significant

^*significant decrease in Cefotaxime Intermediate resistance level among strains between PCV7 vs. PCV13